Title : A randomized, placebo-controlled, double-blind, phase 3 trial to evaluate the efficacy and safety of anagliptin in drug-naïve patients with type 2 diabetes.

Pub. Date : 2015

PMID : 25819061






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. anagliptin dipeptidyl peptidase 4 Homo sapiens
2 Plasma dipeptidyl peptidase (DPP)-4 activity was significantly inhibited after 24 weeks of anagliptin treatment, and >75% and >90% inhibitions were observed during the meal tolerance tests with 100 mg and 200 mg anagliptin, respectively. anagliptin dipeptidyl peptidase 4 Homo sapiens
3 Twice-daily anagliptin therapy effectively inhibited DPP-4 activity and improved glycemic control and was well-tolerated in patients with type 2 diabetes. anagliptin dipeptidyl peptidase 4 Homo sapiens